142 related articles for article (PubMed ID: 17275669)
1. 3-methylcrotonyl-CoA carboxylase deficiency and severe multiple sclerosis.
Darin N; Andersen O; Wiklund LM; Holmgren D; Holme E
Pediatr Neurol; 2007 Feb; 36(2):132-4. PubMed ID: 17275669
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.
Minagar A; Alexander JS; Schwendimann RN; Kelley RE; Gonzalez-Toledo E; Jimenez JJ; Mauro L; Jy W; Smith SJ
Arch Neurol; 2008 Feb; 65(2):199-204. PubMed ID: 18071030
[TBL] [Abstract][Full Text] [Related]
3. The use of interferon beta in relapsing-remitting multiple sclerosis.
Etheridge LJ; Beverley DW; Ferrie C; McManus E
Arch Dis Child; 2004 Aug; 89(8):789-91. PubMed ID: 15269086
[TBL] [Abstract][Full Text] [Related]
4. Magnetic resonance imaging as a surrogate for treatment effect on multiple sclerosis relapses.
Arnold DL; Goodin DS
Ann Neurol; 2009 Mar; 65(3):237-8. PubMed ID: 19334057
[No Abstract] [Full Text] [Related]
5. Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy.
Zivadinov R; Locatelli L; Cookfair D; Srinivasaraghavan B; Bertolotto A; Ukmar M; Bratina A; Maggiore C; Bosco A; Grop A; Catalan M; Zorzon M
Mult Scler; 2007 May; 13(4):490-501. PubMed ID: 17463072
[TBL] [Abstract][Full Text] [Related]
6. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
Koch-Henriksen N; Sorensen PS; Bendtzen K; Flachs EM
Mult Scler; 2009 May; 15(5):601-5. PubMed ID: 19299439
[TBL] [Abstract][Full Text] [Related]
7. 3-Methylcrotonyl-CoA carboxylase deficiency. A long-term outcome.
Al-Odaib A; Rashed M; Page T; Nyhan W; Ozand PT
Saudi Med J; 2006 May; 27(5):732-3. PubMed ID: 16680273
[No Abstract] [Full Text] [Related]
8. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis.
Birnbaum G; Cree B; Altafullah I; Zinser M; Reder AT
Neurology; 2008 Oct; 71(18):1390-5. PubMed ID: 18525027
[TBL] [Abstract][Full Text] [Related]
9. A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis.
Goodin DS
Neurology; 2006 Oct; 67(7):1313-4. PubMed ID: 17030783
[No Abstract] [Full Text] [Related]
10. Long time interval between multiple sclerosis onset and occurrence of primary Sjögren's syndrome in a woman treated with interferon-beta.
De Santi L; Costantini MC; Annunziata P
Acta Neurol Scand; 2005 Sep; 112(3):194-6. PubMed ID: 16097964
[TBL] [Abstract][Full Text] [Related]
11. A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis.
Durelli L; Barbero P; Clerico M;
Neurology; 2006 Dec; 67(12):2264; author reply 2264-5. PubMed ID: 17190964
[No Abstract] [Full Text] [Related]
12. Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon-beta 1a, and high doses of immunoglobulins.
Sarchielli P; Zaffaroni M; Floridi A; Greco L; Candeliere A; Mattioni A; Tenaglia S; Di Filippo M; Calabresi P
Mult Scler; 2007 Apr; 13(3):313-31. PubMed ID: 17439900
[TBL] [Abstract][Full Text] [Related]
13. Recurrent attacks of status epilepticus as predominant symptom in 3-methylcrotonyl-CoA carboxylase deficiency.
Dirik E; Yiş U; Paşaoğlu G; Chambaz C; Baumgartner MR
Brain Dev; 2008 Mar; 30(3):218-20. PubMed ID: 17869468
[TBL] [Abstract][Full Text] [Related]
14. Anaplastic oligodendroglioma and gliomatosis type 2 in interferon-beta treated multiple sclerosis patients. Report of two cases.
Sega S; Horvat A; Popovic M
Clin Neurol Neurosurg; 2006 Mar; 108(3):259-65. PubMed ID: 16378678
[TBL] [Abstract][Full Text] [Related]
15. Multiple sclerosis in Pakistan.
Wasay M; Ali S; Khatri IA; Hassan A; Asif M; Zakiullah N; Ahmed A; Malik A; Khealani B; Haq A; Fredrikson S
Mult Scler; 2007 Jun; 13(5):668-9. PubMed ID: 17548448
[TBL] [Abstract][Full Text] [Related]
16. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
Río J; Rovira A; Tintoré M; Huerga E; Nos C; Tellez N; Tur C; Comabella M; Montalban X
Mult Scler; 2008 May; 14(4):479-84. PubMed ID: 18562504
[TBL] [Abstract][Full Text] [Related]
17. Progressive multifocal leukoencephalopathy, natalizumab, and multiple sclerosis.
Alvarez-Cermeño JC; Masjuan J; Villar LM
N Engl J Med; 2005 Oct; 353(16):1744-6; author reply 1744-6. PubMed ID: 16240475
[No Abstract] [Full Text] [Related]
18. Benefits of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis.
Johnson KP; Due DL
Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):205-14. PubMed ID: 19527092
[TBL] [Abstract][Full Text] [Related]
19. Anesthetic management of a patient with 3-methylcrotonyl-CoA carboxylase deficiency.
Robbins KA; León-Ruiz EN
Anesth Analg; 2008 Aug; 107(2):648-50. PubMed ID: 18633047
[TBL] [Abstract][Full Text] [Related]
20. Mitoxantrone treatment in patients with early relapsing-remitting multiple sclerosis.
Cocco E; Marchi P; Sardu C; Russo P; Paolillo A; Mascia M; Solla M; Frau J; Lorefice L; Massole S; Floris G; Marrosu M
Mult Scler; 2007 Sep; 13(8):975-80. PubMed ID: 17468439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
